Search Results

You are looking at 341 - 350 of 2,911 items for :

  • Refine by Access: All x
Clear All
Full access

A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States

Christopher Nevala-Plagemann, Shashank Sama, Jian Ying, Jincheng Shen, Benjamin Haaland, Vaia Florou, and Ignacio Garrido-Laguna

metastatic CRC (mCRC), fluoropyrimidine-based cytotoxic chemotherapy has long been the mainstay of treatment. 2 , 3 Improvements in clinical outcomes have been achieved by combining chemotherapy with an anti–vascular endothelial growth factor (anti

Full access

Acute and Chronic Complications After Treatment of Locoregional Anal Cancer: Prevention and Management Strategies

Leah Katz, David P. Horowitz, and Lisa A. Kachnic

experience significant acute and chronic GI symptoms related to CRT; however, a recent study using patient-reported outcomes (PROs) demonstrated that most patients return to baseline at 3 months status post CRT completion, based on the EPIC questionnaire. 28

Full access

Keynote Session: Reducing Racial Disparities in Oncology—Recommendations for Implementing Guideline-Adherent Cancer Care

Presented by: Shonta Chambers, Elizabeth Harrington, Lisa A. Lacasse, Robert Winn, and moderated by Alyssa A. Schatz

Multiple studies have shown that adherence to guidelines such as the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) improves various cancer care outcomes, including overall survival and quality-of-life measures. 1 – 6 However

Full access

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Featured Updates to the NCCN Guidelines

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo F. Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis E. Fayad, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Mark S. Kaminski, Christopher R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Amitkumar Mehta, Auayporn Nademanee, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth B. Roberts, Stephen D. Smith, Erin D. Snyder, Lode J. Swinnen, Julie M. Vose, Mary A. Dwyer, and Hema Sundar

newly diagnosed NHLs annually. 1 Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients, with an estimated annual rate of 2% to 3%, and is generally associated with a poor clinical outcome. 2 – 4 In a pooled analysis of

Full access

Combined Modality Therapy of Esophageal Cancer

Rosalyn A. Juergens and Arlene Forastiere

Edited by Kerrin G. Robinson

Harpole DH . Outcomes after esophagectomy: a ten-year prospective cohort . Ann Thorac Surg 2003 ; 75 : 217 – 222 ; discussion 222 . 33. Stahl M Walz MK Stuschke M . Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy

Full access

Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults

Kah Poh Loh, Vivian Lam, Katey Webber, Simran Padam, Mina S. Sedrak, Vivek Musinipally, Madison Grogan, Carolyn J. Presley, Janice Grandi, Chandrika Sanapala, Daniel A. Castillo, Grace DiGiovanni, Supriya G. Mohile, Louise C. Walter, and Melisa L. Wong

critically important to patients. More than 70% of older patients with cancer report that they would not choose a treatment that results in functional impairment, even if it improves survival. 11 Despite the importance of functional outcomes to older adults

Full access

High-Risk of Adverse Pathologic Features in Patients With Clinical T1 High-Grade Bladder Cancer Undergoing Radical Cystectomy

Richard S. Matulewicz, Brendan T. Frainey, Daniel T. Oberlin, and Joshua J. Meeks

-risk” population of patients with T1HG bladder cancer and determine the subset of these patients receiving RC, (2) determine factors associated with patients receiving RC versus bladder-sparing procedures, and (3) describe the pathologic and oncologic outcomes

Full access

Influence of Treating Facility, Provider Volume, and Patient-Sharing on Survival of Patients With Multiple Myeloma

Ashley T. Freeman, May Kuo, Lei Zhou, Justin G. Trogdon, Chris D. Baggett, Sascha A. Tuchman, Thomas C. Shea, and William A. Wood

at low-volume facilities. Superior survival has also been reported for patients with chronic lymphocytic leukemia (CLL) treated by a CLL specialist compared with other hematologists within a single NCICCC. 5 Recently, Go et al 6 identified a volume–outcome

Full access

Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review

Ghadeer Olleik, Wassim Kassouf, Armen Aprikian, Jason Hu, Marie Vanhuyse, Fabio Cury, Stuart Peacock, Elin Bonnevier, Ebba Palenius, and Alice Dragomir

, approximately 220,800 men are diagnosed with PCa and 27,000 men die of the disease per year. 3 Early detection of PCa results in high cure rates, better outcomes, and lower costs. 4 , 5 Currently, detection and clinical staging depend on serum prostate

Full access

Oncology Research Program

. Four different dose schedules of perifosine with temsirolimus will be tested. Primary Outcome Measures: Maximum tolerated dose (MTD) of combination perifosine and temsirolimus in children with cancer Secondary Outcome Measures: Determine